LORNOXICAM: A REVIEW OF ITS THERAPEUTIC POTENTIAL IN DIFFERENT CLINICAL STUDIES

  • Sushila Godara Post Graduate Institute of Medical Sciences, Rohtak
  • R K Srivastava Post Graduate Institute of Medical Sciences, Rohtak
  • Rajesh Godara Post Graduate Institute of Medical Sciences, Rohtak
  • Garima Bhutani Post Graduate Institute of Medical Sciences, Rohtak, BPS, govt. medical college, Khanpur Kalan Sonipat, Haryana, India.

Abstract

Lornoxicam is a member of the oxicam group of nonsteroidal antiinflammatory drugs (NSAIDs), producing analgesic and antipyretic effects  through the non-selective inhibition of cyclo-oxygenase-1 and -2. Besides its inhibitory effect on COX1 and COX-2 peripheral receptors, is also increases endogenous dinorphin and beta-endorphin levels promoting central analgesic and anti-inflammatory effects. Recently, lornoxicam has been introduced in Indian market in oral, intravenous and intramuscular formulations.  Lornoxicam is completely absorbed after oral administration, reaching peak plasma concentrations of 280 mg/L within 2.5 hours after a 4 mg dose.  After intramuscular injection maximum plasma concentrations are achieved after approximately 20-25 minutes. Lornoxicam is extensively metabolished in liver by cytochrome P4502DC9 to inactive metabolite 5’-hydroxy-lornoxicam. The mean elimination half life is 3 to 4 hours. There is plenty of literature available on the effect of lornoxicam on chronic and acute pain management. These preliminary finding require confirmation in further comparative studies.

Key words:- lornoxicam, analgesic, anti inflammatory drugs.

Downloads

Download data is not yet available.
Statistics
108 Views | 459 Downloads
How to Cite
Godara, S., Srivastava, R., Godara, R., & Bhutani, G. (2013). LORNOXICAM: A REVIEW OF ITS THERAPEUTIC POTENTIAL IN DIFFERENT CLINICAL STUDIES. Journal of Drug Delivery and Therapeutics, 3(2). https://doi.org/10.22270/jddt.v3i2.403